BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11174334)

  • 1. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
    Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
    Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S; Kim JO; Methe H
    Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
    Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
    Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
    Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
    Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
    Furenes EB; Arnesen H; Solheim S; Grøgaard HK; Hoffmann P; Seljeflot I
    Thromb Res; 2009 Nov; 124(5):560-4. PubMed ID: 19410278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction.
    Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Clark LT; Pinsky DJ; Marmur JD
    Am Heart J; 2006 May; 151(5):1101.e1-8. PubMed ID: 16644343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
    Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
    Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.
    Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D
    Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome.
    Shu J; Ren N; Du JB; Zhang M; Cong HL; Huang TG
    Scand Cardiovasc J; 2007 Jun; 41(3):149-54. PubMed ID: 17487763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes and relations of soluble plasma CD40L and matrix metalloproteinase-9 levels in patients with coronary heart disease].
    Li J; Zhao SP; Peng DQ; Zhou HN
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):517-20. PubMed ID: 16137036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
    Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation.
    Gresele P; Falcinelli E; Loffredo F; Cimmino G; Corazzi T; Forte L; Guglielmini G; Momi S; Golino P
    Eur Heart J; 2011 Feb; 32(3):316-25. PubMed ID: 21036774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.